NASDAQ:PPBT Purple Biotech (PPBT) Stock Price, News & Analysis $3.51 -0.27 (-7.14%) Closing price 04:00 PM EasternExtended Trading$3.59 +0.08 (+2.28%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Purple Biotech Stock (NASDAQ:PPBT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Purple Biotech alerts:Sign Up Key Stats Today's Range$3.47▼$3.9950-Day Range$3.69▼$4.9552-Week Range$3.47▼$29.00Volume20,174 shsAverage Volume12,367 shsMarket Capitalization$4.49 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingHold Company Overview Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. Read More Purple Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScorePPBT MarketRank™: Purple Biotech scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingPurple Biotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialPurple Biotech has a consensus price target of $30.00, representing about 754.7% upside from its current price of $3.51.Amount of Analyst CoveragePurple Biotech has only been the subject of 3 research reports in the past 90 days.Read more about Purple Biotech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Purple Biotech are expected to grow in the coming year, from ($16.50) to ($6.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Purple Biotech is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Purple Biotech is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPurple Biotech has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Purple Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.84% of the float of Purple Biotech has been sold short.Short Interest Ratio / Days to CoverPurple Biotech has a short interest ratio ("days to cover") of 0.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Purple Biotech has recently increased by 31.47%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPurple Biotech does not currently pay a dividend.Dividend GrowthPurple Biotech does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.75 News SentimentPurple Biotech has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Purple Biotech this week, compared to 1 article on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Purple Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders2.98% of the stock of Purple Biotech is held by insiders.Percentage Held by Institutions9.64% of the stock of Purple Biotech is held by institutions.Read more about Purple Biotech's insider trading history. Receive PPBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPBT Stock News HeadlinesReviewing Equillium (NASDAQ:EQ) & Purple Biotech (NASDAQ:PPBT)May 19 at 3:27 AM | americanbankingnews.comPurple Biotech Reports First Quarter 2026 Financial Results and Business HighlightsMay 16 at 12:53 AM | markets.businessinsider.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 19 at 1:00 AM | Brownstone Research (Ad)Purple Biotech (PPBT) Projected to Post Quarterly Earnings on WednesdayMay 13, 2026 | americanbankingnews.comPurple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240April 27, 2026 | markets.businessinsider.comPurple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody PlatformApril 23, 2026 | markets.businessinsider.comPurple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody PlatformMarch 25, 2026 | markets.businessinsider.comPurple Biotech Regains Compliance with NasdaqMarch 17, 2026 | finance.yahoo.comSee More Headlines PPBT Stock Analysis - Frequently Asked Questions How have PPBT shares performed this year? Purple Biotech's stock was trading at $6.5750 at the beginning of the year. Since then, PPBT shares have decreased by 46.6% and is now trading at $3.51. How were Purple Biotech's earnings last quarter? Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) released its earnings results on Friday, May, 15th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.29. When did Purple Biotech's stock split? Purple Biotech's stock reverse split before market open on Monday, March 2nd 2026.The 1-10 reverse split was announced on Wednesday, February 11th 2026. The number of shares owned by shareholders was adjusted after the market closes on Sunday, March 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Purple Biotech IPO? Purple Biotech (PPBT) raised $13 million in an initial public offering (IPO) on Friday, November 20th 2015. The company issued 3,158,900 shares at $4.13 per share. How do I buy shares of Purple Biotech? Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Purple Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Purple Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), GE Aerospace (GE), Adobe (ADBE) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings5/15/2026Today5/19/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (52m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PPBT's financial health is in the Red zone, according to TradeSmith. PPBT has been in this zone for over 52 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PPBT Previous SymbolNASDAQ:KTOV CIK1614744 Webwww.kitovpharma.com Phone(723) 933-3121Fax972-153-39333121Employees20Year FoundedN/APrice Target and Rating Average Price Target for Purple Biotech$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+754.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($18.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.39 million Net MarginsN/A Pretax MarginN/A Return on Equity-104.75% Return on Assets-85.77% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.52 per share Price / Book0.47Miscellaneous Outstanding Shares1,280,000Free Float1,247,000Market Cap$4.49 million OptionableOptionable Beta0.68 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:PPBT) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
